WO2011024146A3 - Adam12 inhibitors and their use against inflammation-induced fibrosis - Google Patents
Adam12 inhibitors and their use against inflammation-induced fibrosis Download PDFInfo
- Publication number
- WO2011024146A3 WO2011024146A3 PCT/IB2010/053865 IB2010053865W WO2011024146A3 WO 2011024146 A3 WO2011024146 A3 WO 2011024146A3 IB 2010053865 W IB2010053865 W IB 2010053865W WO 2011024146 A3 WO2011024146 A3 WO 2011024146A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- adam12
- induced fibrosis
- inflammation
- use against
- inhibitors
- Prior art date
Links
- 206010016654 Fibrosis Diseases 0.000 title abstract 4
- 206010061218 Inflammation Diseases 0.000 title abstract 4
- 230000004761 fibrosis Effects 0.000 title abstract 4
- 230000004054 inflammatory process Effects 0.000 title abstract 4
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 108091007507 ADAM12 Proteins 0.000 abstract 4
- 238000002679 ablation Methods 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
- 230000002206 pro-fibrotic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/20—Animal model comprising regulated expression system
- A01K2217/203—Animal model comprising inducible/conditional expression system, e.g. hormones, tet
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/20—Animal model comprising regulated expression system
- A01K2217/206—Animal model comprising tissue-specific expression system, e.g. tissue specific expression of transgene, of Cre recombinase
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0368—Animal model for inflammation
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0393—Animal model comprising a reporter system for screening tests
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8527—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic for producing animal models, e.g. for tests or diseases
- C12N2015/859—Animal models comprising reporter system for screening tests
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2820/00—Vectors comprising a special origin of replication system
- C12N2820/55—Vectors comprising a special origin of replication system from bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96486—Metalloendopeptidases (3.4.24)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/08—Hepato-biliairy disorders other than hepatitis
- G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/38—Pediatrics
- G01N2800/382—Cystic fibrosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Environmental Sciences (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Plant Pathology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/393,113 US20120225082A1 (en) | 2009-08-28 | 2010-08-27 | ADAM12 Inhibitors and Their Use Against Inflammation-Induced Fibrosis |
EP17195306.0A EP3358351B1 (en) | 2009-08-28 | 2010-08-27 | Adam12 inhibitors and their use against inflammation-induced fibrosis |
EP10754592.3A EP2470909B1 (en) | 2009-08-28 | 2010-08-27 | Adam12 inhibitors and their use against inflammation-induced fibrosis |
US14/479,006 US9777276B2 (en) | 2009-08-28 | 2014-09-05 | ADAM12 inhibitors and their use against inflammation-induced fibrosis |
US15/690,076 US10961536B2 (en) | 2009-08-28 | 2017-08-29 | ADAM12 inhibitors and their use against inflammation-induced fibrosis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2,676,946 | 2009-08-28 | ||
CA2676946A CA2676946A1 (en) | 2009-08-28 | 2009-08-28 | Adam12 inhibitors and their use against inflammation-induced fibrosis |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/393,113 A-371-Of-International US20120225082A1 (en) | 2009-08-28 | 2010-08-27 | ADAM12 Inhibitors and Their Use Against Inflammation-Induced Fibrosis |
US14/479,006 Division US9777276B2 (en) | 2009-08-28 | 2014-09-05 | ADAM12 inhibitors and their use against inflammation-induced fibrosis |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011024146A2 WO2011024146A2 (en) | 2011-03-03 |
WO2011024146A3 true WO2011024146A3 (en) | 2011-06-16 |
Family
ID=43614065
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2010/053865 WO2011024146A2 (en) | 2009-08-28 | 2010-08-27 | Adam12 inhibitors and their use against inflammation-induced fibrosis |
Country Status (4)
Country | Link |
---|---|
US (3) | US20120225082A1 (en) |
EP (2) | EP3358351B1 (en) |
CA (1) | CA2676946A1 (en) |
WO (1) | WO2011024146A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2676946A1 (en) | 2009-08-28 | 2011-02-28 | Lucie Peduto | Adam12 inhibitors and their use against inflammation-induced fibrosis |
EP2990043B1 (en) * | 2013-04-25 | 2018-09-05 | Yamaguchi University | Inhibitors of adam12 for use in treating neurological disorders |
WO2017134265A1 (en) * | 2016-02-05 | 2017-08-10 | Institut Pasteur | Use of inhibitors of adam12 as adjuvants in tumor therapies |
CN113350368B (en) * | 2021-07-21 | 2023-07-11 | 山东科金生物发展有限公司 | Application of gene inhibitor in preparation of epidermal stem cell migration pharmaceutical preparation |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0342682A2 (en) * | 1988-05-19 | 1989-11-23 | Warner-Lambert Company | Hydroxamate derivatives of selected nonsteroidal anti-inflammatory acyl residues having cyclooxygenase and 5-lipoxygenase inhibition |
WO1997040072A2 (en) * | 1996-04-19 | 1997-10-30 | The University Of Sheffield | Adam proteins and uses thereof |
WO2006014903A2 (en) * | 2004-07-27 | 2006-02-09 | Five Prime Therapeutics, Inc. | Compositions and methods of use for adam12 antagonists in treating disease |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4595700A (en) | 1984-12-21 | 1986-06-17 | G. D. Searle & Co. | Thiol based collagenase inhibitors |
US4681894A (en) | 1986-09-26 | 1987-07-21 | Ortho Pharmaceutical Corporation | Hydroxamic acids and esters |
US5892112A (en) | 1990-11-21 | 1999-04-06 | Glycomed Incorporated | Process for preparing synthetic matrix metalloprotease inhibitors |
EP0639982A1 (en) | 1992-05-01 | 1995-03-01 | British Biotech Pharmaceuticals Limited | Use of mmp inhibitors |
GB9405076D0 (en) | 1994-03-16 | 1994-04-27 | Inst Of Ophtalmology | A medical use of matrix metalloproteinase inhibitors |
WO1995029689A1 (en) | 1994-04-28 | 1995-11-09 | Merck & Co., Inc. | N-carboxyalkyl derivatives as antidegenerative active agents |
US5968795A (en) | 1996-05-15 | 1999-10-19 | Bayer Corporation | Biaryl acetylenes as inhibitors of matrix metalloproteases |
US5925637A (en) | 1997-05-15 | 1999-07-20 | Bayer Corporation | Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids |
US6174915B1 (en) | 1997-03-25 | 2001-01-16 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
AU4074799A (en) | 1998-05-14 | 1999-11-29 | Du Pont Pharmaceuticals Company | Substituted aryl hydroxamic acids as metalloproteinase inhibitors |
HUP0102714A3 (en) | 1998-07-30 | 2003-01-28 | Warner Lambert Co | Tricyclic sulfonamid derivatives as inhibitors of matrix metalloproteinases and medicaments containing the same |
PT1819359E (en) * | 2004-12-09 | 2015-05-28 | Janssen Biotech Inc | Anti-integrin immunoconjugates, methods of their production and their use |
AR070127A1 (en) * | 2008-01-11 | 2010-03-17 | Novartis Ag | PIRROLO - PIRIMIDINAS AND PIRROLO -PIRIDINAS |
AU2009322184B2 (en) * | 2008-12-04 | 2016-03-31 | Lankenau Institute For Medical Research | Compositions and methods for the treatment and prevention of lens fibrotic diseases |
CA2676946A1 (en) | 2009-08-28 | 2011-02-28 | Lucie Peduto | Adam12 inhibitors and their use against inflammation-induced fibrosis |
US8703128B2 (en) * | 2011-01-24 | 2014-04-22 | New York University | Methods of modulating TGFβ signaling |
-
2009
- 2009-08-28 CA CA2676946A patent/CA2676946A1/en not_active Abandoned
-
2010
- 2010-08-27 EP EP17195306.0A patent/EP3358351B1/en active Active
- 2010-08-27 US US13/393,113 patent/US20120225082A1/en not_active Abandoned
- 2010-08-27 EP EP10754592.3A patent/EP2470909B1/en active Active
- 2010-08-27 WO PCT/IB2010/053865 patent/WO2011024146A2/en active Application Filing
-
2014
- 2014-09-05 US US14/479,006 patent/US9777276B2/en active Active
-
2017
- 2017-08-29 US US15/690,076 patent/US10961536B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0342682A2 (en) * | 1988-05-19 | 1989-11-23 | Warner-Lambert Company | Hydroxamate derivatives of selected nonsteroidal anti-inflammatory acyl residues having cyclooxygenase and 5-lipoxygenase inhibition |
WO1997040072A2 (en) * | 1996-04-19 | 1997-10-30 | The University Of Sheffield | Adam proteins and uses thereof |
WO2006014903A2 (en) * | 2004-07-27 | 2006-02-09 | Five Prime Therapeutics, Inc. | Compositions and methods of use for adam12 antagonists in treating disease |
Non-Patent Citations (2)
Title |
---|
JORGENSEN LOUISE HELSKOV ET AL: "Transgenic overexpression of ADAM12 suppresses muscle regeneration and aggravates dystrophy in aged mdx mice", AMERICAN JOURNAL OF PATHOLOGY, vol. 171, no. 5, November 2007 (2007-11-01), pages 1599 - 1607, XP002631501, ISSN: 0002-9440 * |
PAULISSEN GENEVIEVE ET AL: "Expression of ADAMs and their inhibitors in sputum from patients with asthma", MOLECULAR MEDICINE (BALTIMORE), vol. 12, no. 7-8, July 2006 (2006-07-01), pages 171 - 179, XP002631502, ISSN: 1076-1551 * |
Also Published As
Publication number | Publication date |
---|---|
US9777276B2 (en) | 2017-10-03 |
US20120225082A1 (en) | 2012-09-06 |
CA2676946A1 (en) | 2011-02-28 |
US20170369888A1 (en) | 2017-12-28 |
EP3358351A1 (en) | 2018-08-08 |
EP2470909A2 (en) | 2012-07-04 |
US20150005367A1 (en) | 2015-01-01 |
US10961536B2 (en) | 2021-03-30 |
WO2011024146A2 (en) | 2011-03-03 |
EP2470909B1 (en) | 2017-11-15 |
EP3358351B1 (en) | 2021-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010129467A8 (en) | Compounds and methods for inhibition of renin, and indications therefor | |
WO2012065958A9 (en) | Method of treating contrast-induced nephropathy | |
EP2054380B8 (en) | Trypsin-like serine protease inhibitors, and their preparation and use | |
ZA201007199B (en) | Thiazol-4-carboxylic acid esters and thioesters as plant protection agents | |
WO2006037981A8 (en) | Inhibition of tumour cell migration | |
EP2148693A4 (en) | Alpha-i antitrypsin having no significant serine protease inhibitor activity | |
WO2010002956A3 (en) | Heterocyclic derivatives as modulators of ion channels | |
WO2010132882A3 (en) | Sublingual dexmedetomidine compositions and methods of use thereof | |
WO2009089494A3 (en) | Pharmaceutical compositions | |
WO2007146284A3 (en) | Thienopyrimidines useful as modulators of ion channels | |
WO2008137816A8 (en) | Tricyclic compounds as matrix metalloproteinase inhibitors | |
WO2008087643A3 (en) | Methods for enhancing the therapeutic efficacy of topoisomerase inhibitors | |
ZA201100560B (en) | Pest-control compositions and methods having high target and low non-target activity | |
EP2712291A4 (en) | N1- and n2-carbamoyl-1,2,3-triazole serine hydrolase inhibitors and methods | |
HK1115379A1 (en) | 5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other diseases 5-- | |
EP2219666A4 (en) | Prostatic acid phosphatase for the treatment of pain | |
WO2012037547A3 (en) | Methods and compositions for inhibiting autophagy for the treatment of fibrosis | |
WO2012027482A3 (en) | Compounds, compositions and methods related to ppar antagonists | |
WO2010074936A3 (en) | Enzastaurin for the treatment of cancer | |
WO2011024146A3 (en) | Adam12 inhibitors and their use against inflammation-induced fibrosis | |
WO2011083482A3 (en) | Method for treatment of psoriasis | |
WO2007130575A3 (en) | Protection against oxidative damage in cells | |
EP2023925A4 (en) | Cdki pathway inhibitors as selective inhibitors of tumor cell growth | |
EP2078174B8 (en) | Water treatment plant | |
IL213136A0 (en) | Compositions comprising renin-angiotensin aldosterone system inhibitors and lipoic acid compounds, and the use thereof for the treatment of renin-angiotensin aldosterone system related disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10754592 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2010754592 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010754592 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10754592 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13393113 Country of ref document: US |